Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic Incontinence Device Appears Set For Favorable MCAC Review

This article was originally published in The Gray Sheet

Executive Summary

Medtronic's InterStim sacral nerve stimulation (SNS) device for urinary incontinence is apparently poised for the first favorable review by the Medicare Coverage Advisory Commission (MCAC), based on a technical assessment prepared by the Technology Evaluation Center (TEC) of the Blue Cross/Blue Shield Association.

You may also be interested in...



Medtronic InterStim On Track For Medicare Coverage After MCAC Review

The Medicare Coverage Advisory Committee's Medical/Surgical Procedures panel gave wide discretion to the Health Care Financing Administration to determine whether Medtronic's InterStim sacral nerve stimulation (SNS) device for urinary incontinence should be reimbursed prior to, or following, surgery.

Medtronic InterStim On Track For Medicare Coverage After MCAC Review

The Medicare Coverage Advisory Committee's Medical/Surgical Procedures panel gave wide discretion to the Health Care Financing Administration to determine whether Medtronic's InterStim sacral nerve stimulation (SNS) device for urinary incontinence should be reimbursed prior to, or following, surgery.

MCAC Will Review E-stim As Adjunctive Therapy For Wound Healing

The Medicare Coverage Advisory Committee will review electrical stimulation for the treatment of chronic wounds as an adjunctive therapy, following a recommendation by the American Physical Therapy Association to the Health Care Financing Administration.

UsernamePublicRestriction

Register

OM002075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel